Key clinical point: Combination strategies that include immunotherapeutic agents could soon become the future of breast cancer treatment.
Major finding: Immune checkpoint blockade agents are the most studied type of immunotherapy in breast cancer today.
Study details: A narrative review summarizing current immunotherapeutic agents in the treatment of breast cancer.
Disclosures: No funding sources were reported. The authors reported financial affiliations with Amgen, Celgene, Genentech, Eli Lilly, Ipsen, Novartis, Pfizer, and several others.
Adams S et al. JAMA Oncol. 2019 Apr 11. doi: 10.1001/jamaoncol.2018.7147.